Drug shortages

Insulin Glargine-aglr Injection

Eli Lilly and Co.

To Be Discontinued0002-8980-05Endocrinology/Metabolism
Open FDA's page for this record
Discontinued date
09/01/2026
Update type
New
Initial posting date
09/01/2026
Package NDC
0002-8980-05
Generic name
Insulin Glargine-aglr Injection
Contact info
800-545-5979
Update date
09/01/2026
Dosage form
Injection
Presentation
Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
Company name
Eli Lilly and Co.
Status
To Be Discontinued
Related info

A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.

Therapeutic category
Endocrinology/Metabolism
Harmonized identifiers (openFDA)
Application number
BLA761215
Brand name
REZVOGLAR KWIKPEN
Generic name
INSULIN GLARGINE-AGLR
Manufacturer name
Eli Lilly and Company
Product NDC
0002-8980
Product type
HUMAN PRESCRIPTION DRUG
Route
SUBCUTANEOUS
Substance name
INSULIN GLARGINE
RxCUI
2589008, 2589014
SPL ID
a9e95b4c-e280-4bef-a3dd-4907bfad6b4d
SPL set ID
f6af8706-2058-4fe1-99c8-43684c20bfa2
Package NDC
0002-8980-01, 0002-8980-05
Nui
M0011417, N0000175453
Pharm class cs
Insulin [CS]
Pharm class epc
Insulin Analog [EPC]
UNII
2ZM8CX04RZ
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.